Preventing infections in hemodialysis patients with antibiotics
Official title: Prophylactic Antibiotic Treatment in End Stage Kidney Disease and Central Venous Catheter as Hemodialysis Vascular Access
Run by Zealand University Hospital · NCT05248620 · Data updated 2026-11-12
This study is testing if giving antibiotics to people starting hemodialysis can help prevent serious infections during their treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | Zealand University Hospital Academic / other |
| Locations | 7 sites (Copenhagen, Capital Region and 6 other locations) |
| Status | Recruiting |
| Started | February 14, 2022 |
| Main results expected | October 2028 |
| Study ends | May 2029 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT05248620 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with end-stage kidney disease requiring hemodialysis via a central venous catheter.
✕Probably not a fit
Patients who are intolerant to beta-lactam antibiotics or clindamycin, or those with active infections being treated with antibiotics will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of prophylactic antibiotic treatment in preventing blood stream infections and severe culture negative infections in patients starting hemodialysis with a central venous catheter. Eligible participants will be randomly assigned to receive either amoxicillin/clavulanic acid or a placebo before each hemodialysis session for a duration of six months. The study aims to establish a sufficient concentration of antibiotics during dialysis sessions to reduce infection rates. Participants will be monitored for side effects and followed up for one year after treatment.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of infections in hemodialysis patients, improving their overall health outcomes.
How similar studies have gone: Previous studies have shown promising results with prophylactic antibiotics in similar patient populations, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft)) * ≥18 years * Ability to understand the study background, risk and benefit of treatment and to give written informed consent Exclusion Criteria: * Unable to give informed consent * Known intolerance to beta-lactam antibiotics and clindamycin * Active infection treated with antibiotics * Breastfeeding * Pregnancy. In women of childbearing age, an approved birth control must be ensured at least 1 month before and during all the 6 months of antibiotic/placebo treatment. Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible.
Where it's running
-
Herlev-Gentofte Hospital
Copenhagen, Capital Region, Denmark Recruiting -
Aalborg University Hospital
Aalborg, North Region, Denmark Recruiting -
ZUH Roskilde
Roskilde, Region Sjælland, Denmark Recruiting -
Odense University Hospital
Odense, Region South, Denmark Recruiting -
Rigshospitalet
Copenhagen, Capital Region, Denmark Not yet recruiting -
North Zealand Hospital Hillerød
Hillerød, Capital Region, Denmark Not yet recruiting
Show 1 more location
-
Aarhus University Hospital
Aarhus, Middle Region, Denmark Not yet recruiting
Study contacts
- Principal investigator: Niels E Bruun, Professor — Dept. cardiology, Zealand University Hospital, Roskilde, Denmark
- Study coordinator: Niels E Bruun, Professor
- Email: nbru@regionsjaelland.dk
- Phone: +4525159309
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bioimpedance Spectroscopy for Fluid Changes in Hemodialysis Patients
This study tests whether raw bioimpedance data can help doctors gauge fluid changes in people on hemodialysis and guides fluid removal decisions.
-
Nurse-led dialysis self-management program for distress in adults on hemodialysis
A nurse-led program helps adults on hemodialysis see if structured self-management support reduces dialysis-related distress compared to routine care.
-
Repeated brief limb ischemia to see its effect on blood pressure and inflammation in people with kidney disease
This study tests whether short, repeated episodes of limb ischemia can influence blood pressure, heart rate, and inflammation in adults with chronic kidney disease who may be on hemodialysis.
-
Mindfulness Meditation for Hemodialysis Patients
A small trial tests whether a 4-week mindfulness meditation program in addition to usual care can improve sleep quality and reduce stress and symptoms in adults on hemodialysis.
-
Progressive muscle relaxation to ease depression and fatigue during hemodialysis
This trial will try whether guided progressive muscle relaxation can reduce depression and fatigue in people receiving hemodialysis.
-
Multispecies synbiotic in people on hemodialysis
This pilot study tests whether a multispecies synbiotic can alter gut microbes and reduce gut-derived toxins in adults on maintenance hemodialysis over 12 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.